57 related articles for article (PubMed ID: 2786553)
1. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.
Choi BS; Sondel PM; Hank JA; Schalch H; Gan J; King DM; Kendra K; Mahvi D; Lee LY; Kim K; Albertini MR
Cancer Immunol Immunother; 2006 Jul; 55(7):761-74. PubMed ID: 16187086
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects.
Thompson JA; Cox WW; Lindgren CG; Collins C; Neraas KA; Bonnem EM; Fefer A
Cancer Immunol Immunother; 1987; 25(1):47-53. PubMed ID: 3109737
[TBL] [Abstract][Full Text] [Related]
3. Combined effects of interferon alpha and interleukin 2 on the induction of a vascular leak syndrome in mice.
Puri RK; Rosenberg SA
Cancer Immunol Immunother; 1989; 28(4):267-74. PubMed ID: 2495179
[TBL] [Abstract][Full Text] [Related]
4. Immunomodulatory effects of ultra-low-dose interleukin-2 in cancer patients: a phase-IB study.
Lindemann A; Brossart P; Höffken K; Flasshove M; Voliotis D; Diehl V; Hecker G; Wagner H; Mertelsmann R
Cancer Immunol Immunother; 1993 Oct; 37(5):307-15. PubMed ID: 8402734
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-alpha A (rIFN alpha A).
Eggermont AM; Weimar W; Tank B; Dekkers-Bijma AM; Marquet RL; Lameris JS; Westbroek DL; Jeekel J
Cancer Immunol Immunother; 1986; 21(1):81-4. PubMed ID: 3632919
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of recombinant interferon gamma administered by s.c. injection three times per week in patients with solid tumours.
Wagstaff J; Smith D; Nelmes P; Loynds P; Crowther D
Cancer Immunol Immunother; 1987; 25(1):54-8. PubMed ID: 3109738
[TBL] [Abstract][Full Text] [Related]
7. A phase I trial of recombinant gamma interferon in patients with cancer.
Foon KA; Sherwin SA; Abrams PG; Stevenson HC; Holmes P; Maluish AE; Oldham RK; Herberman RB
Cancer Immunol Immunother; 1985; 20(3):193-7. PubMed ID: 3933818
[TBL] [Abstract][Full Text] [Related]
8. IL-2 and Beyond in Cancer Immunotherapy.
Wrangle JM; Patterson A; Johnson CB; Neitzke DJ; Mehrotra S; Denlinger CE; Paulos CM; Li Z; Cole DJ; Rubinstein MP
J Interferon Cytokine Res; 2018 Feb; 38(2):45-68. PubMed ID: 29443657
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of defective monocyte function during immunotherapy with recombinant interferon.
Nielsen H; Ernst P
Cancer Immunol Immunother; 1986; 22(2):144-7. PubMed ID: 3719594
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of ImuVert (natural membrane vesicles associated with ribosomes) in patients with advanced cancer.
Mittelman A; Urban R; Wong G; Ahmed T; Arlin Z
Cancer Immunol Immunother; 1992; 35(5):331-4. PubMed ID: 1394337
[TBL] [Abstract][Full Text] [Related]
11. Cytokine combinations in immunotherapy for solid tumors: a review.
Heaton KM; Grimm EA
Cancer Immunol Immunother; 1993 Sep; 37(4):213-9. PubMed ID: 8348559
[TBL] [Abstract][Full Text] [Related]
12. Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.
Weiner LM; Padavic-Shaller K; Kitson J; Watts P; Krigel RL; Litwin S
Cancer Res; 1991 Aug; 51(15):3910-8. PubMed ID: 1906779
[TBL] [Abstract][Full Text] [Related]
13. Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
Yang SC; Grimm EA; Parkinson DR; Carinhas J; Fry KD; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub LB; Hong WK; Roth JA
Cancer Res; 1991 Jul; 51(14):3669-76. PubMed ID: 1648441
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 and lymphokine activated killer cells: promises and cautions.
Glassman AB
Ann Clin Lab Sci; 1989; 19(1):51-5. PubMed ID: 2644890
[TBL] [Abstract][Full Text] [Related]
15. [Interleukin-2 based immunotherapy of cancer].
Geertsen PF; Hermann GG; Claësson MH; Steven K; Zeuthen J; von der Maase H
Ugeskr Laeger; 1990 Nov; 152(47):3513-7. PubMed ID: 2256204
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of recombinant interleukin-2 and recombinant beta-interferon in refractory neoplastic diseases.
Paolozzi F; Zamkoff K; Doyle M; Konrad M; Bradley EC; Rudolph A; Newman N; Gullo J; Scalzo A; Poiesz B
J Biol Response Mod; 1989 Apr; 8(2):122-39. PubMed ID: 2786553
[TBL] [Abstract][Full Text] [Related]
17. A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.
Krigel RL; Padavic-Shaller KA; Rudolph AR; Litwin S; Konrad M; Bradley EC; Comis RL
Cancer Res; 1988 Jul; 48(13):3875-81. PubMed ID: 3132324
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]